Bli medlem
Bli medlem

Du är här

2016-03-04

Oncology Venture: APO010 screening protocol approved

Hoersholm, Denmark; March 3rd, 2016 - Oncology Venture Sweden AB
(OV:ST) today announced that the screening protocol for APO010 in
Multiple Myeloma (MM) has been approved by the Ethics Committee.
APO010 is a first in class FASLigand anticancer product in the
immuno-oncology field.

OV will now initiate the screening of approximately 150 patients at 4
sites at Danish hematology wards and identify 15 patients with the
highest likelihood of APO010-benefit in a focused phase 2 multi
center study. The Drug Response Predictor (DRP™) uses genomic
information from the individual cancer patient's tumor. If the
product already on shelf is approved, Phase 2 is expected to start
Q2-Q3 2016.

"I look very much forward to initiate the screening of Multiple
Myeloma (MM) patients for eligibility for the proof-of-concept phase
2 trial with APO010. This new immuno- oncology product mimics our
immune system and is a first in class product which we believe can
become a new treatment option in Multiple Myeloma," Said Adjunct
professor Peter Buhl Jensen, M.D., CEO of Oncology Venture.

APO010 is a FAS-ligand drug that only works when the FAS-receptor is
present. To increase response odds OV uses its DRP™ to find the
patients who in the genes of their tumor has a signature that matches
with APO010 and therefore are high likelihood responders. OV will
screen the patients and include only those with the highest
likelihood of response in its phase 2 clinical trial.

About Multiple Myeloma

Multiple myeloma (MM) is a systemic malignancy in the blood affecting
plasma cells. The introduction of high-dose therapy with autologous
stem cell support and introduction of new therapies like the
proteasome inhibitor bortezomib and IMIDs (thalidomide and
lenalidomide) has improved the outcome. In spite of this eventually
all patients will experience progressive disease and continue into
second and later lines of treatment. OV will approach this important
clinical issue by introducing a novel systemic chemotherapeutic
treatment together with a predictive biomarker test.

Based on DRP, APO010 will be developed for use in treatment of
Multiple Myeloma (blood cancer) a market with a turnover of seven
billion USD in 2014.

About APO010

APO010 employing on immune oncology cell signaling strategy to kill
cancer cells. APO010 is a novel chemotherapeutic agent that mimics
cytotoxic T-lymphocyte signaling. The mechanism of action of APO010
is the specific induction of cell death in Fas-expressing cells
through binding to the Fas receptor and activation of
well-characterised Fas-mediated death-receptor pro-apoptotic pathway.
A phase I study has previously been conducted including 26 patients.
In this study the patients were not selected based on likelihood of
benefit from APO010.

About the Drug Response Predictor (DRP™) screening tool

This method builds on the comparison of sensitive and resistant human
cancer cell lines including genomic information from cell lines
combined with clinical tumor biology and clinical correlates in a
systems biology network.

For further information, please contact

Peter Buhl Jensen, CEO

Telephone: +45 21 60 89 22

E-mail: pbj@oncologyventure.com

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development
of anti-cancer drugs via its wholly owned Danish subsidiary Oncology
Venture ApS. Oncology Venture has a license to use Drug Response
Prediction - DRP™ - in order to significantly increase the
probability of success in clinical trials. DRP™ has proven its
ability to provide a statistically significant prediction of clinical
outcomes from drug treatment in cancer patients in 29 of the 37
clinical studies that were examined. The Company uses a model that
alters the odds in comparison with traditional pharmaceutical
development. Instead of treating all patients with a particular type
of cancer, patients are screened first and only those who are most
likely to respond to the treatment will be treated. Via a more
well-defined patient group, the risk and costs are reduced while the
development process becomes more efficient.

The current product portfolio: LiPlaCis™ for Breast Cancer, Irofulven
developed from a fungus for prostate cancer and APO010 - an immuno-
oncology product for Multiple Myeloma.

-----------------------------------------------------------
http://news.cision.com/oncology-venture/r/apo010-screening-protocol-appr...
http://mb.cision.com/Main/12685/9928694/484625.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.